W. BARRY McDONALD,
Interim Chief Executive Officer
W. Barry McDonald has over 35 years of experience in the healthcare industry. During his career, he has acted both as an executive and as a consultant.
Prior to accepting the position as Interim CEO for TSO3 in May 2008, Mr. McDonald held the position of Executive Director at The Sage Group, where he acted as a consultant for TSO3. The Sage Group is an American consulting firm recognized for the quality of its international expertise in the healthcare industry, notably regarding marketing and business development.
Before joining The Sage Group, Mr. McDonald was, notably, Chief Executive Officer at Mast/Hitachi, in addition to heading Hitachi Chemical, which oversaw business development and acquisitions at Hitachi Chemical’s life sciences business. Prior to that, Mr. McDonald was Senior Vice President, sales, marketing and business development at Hycor Biomedical, as well as President and CEO of Photest Diagnostics. Mr. McDonald also serves on the board of directors for Healthcare Providers Direct, a publicly traded company, and Immunomic Therapeutics, a vaccine biotechnology company.
« Return to previous page |
